Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer’s Disease in Relation to Therapeutic Editing Tools

• Published in: Pharmaceutics Vol. 14; no. 6; p. 1270
• Main Authors: Stanciu, Gabriela Dumitrita, Ababei, Daniela Carmen, Rusu, Razvan Nicolae, Bild, Veronica, Tamba, Bogdan-Ionel
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 15-06-2022; MDPI
• Subjects: A673T mutation; Alzheimer's disease; amyloid precursor protein; Brain; Clinical trials; cognitive decline; CRISPR/Cas9; Dementia; Genes; Middle age; Mutation; Neuropathology; Pathogenesis; Pathology; Population; Proteins; Review; therapeutic editing tools; White people; United States > US
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14061270

Alzheimer’s disease (AD) is biologically defined as a complex neurodegenerative condition with a multilayered nature that leads to a progressive decline in cognitive function and irreversible neuronal loss. It is one of the primary diseases among elderly individuals. With an increasing incidence and a high failure rate for pharmaceutical options that are merely symptom-targeting and supportive with many side effects, there is an urgent need for alternative strategies. Despite extensive knowledge on the molecular basis of AD, progress concerning effective disease-modifying therapies has proven to be a challenge. The ability of the CRISPR–Cas9 gene editing system to help identify target molecules or to generate new preclinical disease models could shed light on the pathogenesis of AD and provide promising therapeutic possibilities. Here, we sought to highlight the current understanding of the involvement of the A673T mutation in amyloid pathology, focusing on its roles in protective mechanisms against AD, in relation to the recent status of available therapeutic editing tools.